Now I see why the Anp Board decided to flip the DMD trial in Europe for a shorter time frame trial CG was responsible to change tack ... Like I said before a few here were against the change ! Now we can take confidence that the FDA is prepared to take Phase 2B data as acceptable for a NDA . The elected Board are doing a wonderful job and are streaks ahead more than we can imagine .$$ Be confident in our Board.
ANP Price at posting:
6.3¢ Sentiment: None Disclosure: Held
